Coronary Event Risk Test as a Potential Tool to Predict Cardiovascular Risk in Gout and Hyperuricemia

ABSTRACT: Objective. Gout is linked with an excess risk of cardiovascular disease (CVD) and there is a need for new tests to assess and stratify high-risk patients. The Coronary Event Risk Test (CERT) based on the determination of plasma ceramides is an efficient event and death risk prediction tool. In this brief report, we focused on the application of the CERT score on hyperuricemia and gout patients for the first time. Methods. Plasma was collected in a single center from 94 hyperuricemic patients, 196 gout patients and 53 controls. Liquid chromatography coupled with mass spectrometry was used to determine the ceramide levels. The CERT score was calculated based on the conventionally used algorithm which provides a 12-point scale that classifies patients from low-risk (score 0-2) to high-risk groups (score 10-12). Results. We found significantly elevated CERT score in patients with gout and hyperuricemia compared to healthy controls. Increased and high-risk CERT score (>7) was 2-fold (11.7%, p-value<0.01) and 5.5-fold (31.12%, p-value<0.001) more frequent in hyperuricemic (median = 3) and gout (median = 5) patients, respectively, compared with controls (median = 2). Conclusion. Our findings show that the CERT score can be used to stratify high-risk gout patients independently on conventional CVD markers. Additionally, we found that patients with hyperuricemia also showed increased CERT score and CVD risk. These results show for the first time how the CERT score can be used in rheumatology practice to stratify and manage gout and hyperuricemic patients by this novel predictive tool.

INSTRUMENT(S): ExionLC, QTRAP 6500+

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Blanka Stiburkova  

PROVIDER: MSV000095822 | MassIVE |

REPOSITORIES: MassIVE